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Introduction
The primary requirement for successful gene therapy is the development of a vector which allows sustained expression of the therapeutic gene without any adverse effect on the recipient. The ideal vector should be capable of infecting both dividing and nondividing cells and be able to directly transduce cells in vivo without the need for ex vivo manipulation of target cells. Direct in vivo gene delivery with retroviral vectors has been limited to proliferating cells since cell division is necessary for efficient transduction and integration.
1 Adenoviral (Ad) vectors allow efficient gene transfer into nondividing cells, but expression is transient due to immune response against the Ad proteins that are expressed by the current generation vectors. 2, 3 Nonviral delivery vehicles are promising, but it has been difficult to accomplish efficient delivery and sustained high-level gene expression. 4 Adenoassociated virus (AAV) based vectors have a number of advantages over these systems. First, wild-type AAV is a defective, nonpathogenic parvovirus which requires coinfection with adenovirus or herpes virus for replication. [5] [6] [7] In contrast to retroviruses, these viruses can efficiently infect both dividing and nondividing cells. 8 Second, the vector system for generating rAAV is simple; the AAV terminal repeats are the only cis elements which are necessary and sufficient for replication, packaging and possibly integration. 9 Since rAAV vectors lack virally encoded genes, the undesirable immune responses which limit adenoviral vectors are avoided. Also, rAAV preparations are stable and can be produced at titers of Ͼ10 12 particles/ml. A wide variety of somatic tissues are being explored for the introduction of foreign genes with a view towards gene therapy. Skeletal muscle tissue is an easily accessible target organ for gene delivery since it constitutes 40% of the body weight of an average individual. 11 There are five recent reports demonstrating the potential of sustained gene delivery following administration of rAAV vectors in mouse muscle. 10, [12] [13] [14] [15] We have recently demonstrated the complete correction of a metabolic disease in a mouse model by a single intramuscular injection of rAAV expressing leptin. 16 In most of these reports there is evidence of long-term expression of the transgene following a single dose administration into mouse skeletal muscle. The ultimate utility of this vector system for treating human diseases will depend on optimizing the delivery conditions in larger nonhuman primate models which may be more reflective of human physiology and anatomy.
Erythropoietin (Epo), which is produced in the kidney of the adult, is a key hormone involved in regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocytes. 17, 18 Clinically, Epo is indicated in the treatment of anemia associated with chronic renal failure and in the treatment of thalassemia. 19 The biological effect of Epo gene expression can be monitored by determining the hematocrit levels and the circulating amount of the hormone can be measured by ELISA. The Cynomolgus monkey Epo gene 20 provides an opportunity to study gene expression without the interference of an immune response against the transgene. In this report, rAAV encoding monkey Epo gene (rAAV-cm-Epo) was delivered to skeletal muscle of baboons to establish the efficiency of gene delivery and the longevity of gene expression of a therapeutically relevant protein.
Results
In vitro analysis of viral particles A rAAV stock containing 2 × 10 12 particles/ml was used in the studies described in this paper. Infection of HT1080 cells with different amounts of virus indicate that ( Figure 1 ) cells infected with 5 × 10 9 particles produced 10 800 mIU/10 6 cells per day, which is equivalent to 86.4 ng of Epo per day (1 mIU is equivalent to approximately 8 pg of Epo), while infection with 2 × 10 8 and 1 × 10 9 particles led to production of 480 and 2200 mIU/10 6 cells per day, respectively.
In vivo analysis of rAAV-cm-Epo in mice
The effects of rAAV-cm-Epo in vivo administration were monitored after injection of 2 × 10 11 particles into the tibialis anterior muscle of C57BL/6 mice. As shown in Figure 2a , the circulating levels of Epo began to rise within 1 week (36.1 mIU/ml) of injection and reached a peak by week 7 (65 mIU/ml). The biological effect of rAAV-cm-Epo injection was monitored by measuring the hematocrit. Hematocrit levels closely mirrored the amounts of circulating Epo in the treated mice ( Figure 2b ). Hematocrits steadily rose to week 7 at which point red blood cells represented greater than 90% of the blood volume (Figure 2b) . Remarkably, the mice maintained this high-level hematocrit to week 11 with no apparent deleterious effect. To determine if the Epo levels were affected by an immune response against this foreign transgene, an ELISA assay was developed to detect antibodies against Epo. As a positive control, serum from BALB/c mice, which were injected on two occasions with
Figure 1 Expression of Epo following infection of HT1080 cells. Supernatant was harvested from cells 48 h after infection and analyzed by ELISA. Titers of rAAV-cm-Epo are indicated on X-axis. Bar marked leptin represents background levels of Epo secreted from cells infected with 5 × 10 9 particles of an irrelevant virus (rAAV-m-leptin).
a plasmid encoding Cynomolgus-Epo, was used. This serum sample had been previously shown to immunodeplete monkey Epo from a supernatant of transfected cells (Murphy et al, data not shown). While the positive serum sample had an anti-Epo titer of 4 × 10
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, titers in rAAV-cm-Epo injected and saline-injected mice were 1000-fold lower ( Figure 3 ).
In vivo analysis of rAAV-cm-Epo in baboons
To assess the effects of rAAV-cm-Epo treatment in a primate model, two 1-year-old baboons weighing 3.5 and 4.0 kg (approximately 150-200 times larger than C57BL/6 mice), were injected with 2 × 10 12 rAAV-cm-Epo particles (10-fold more than mice). Before injection, baboons were monitored for 2 months to determine the baseline values for circulating serum Epo and hematocrit. As shown in Figure 4a , pre-injection values for serum Epo range from 1.5-3.3 mIU/ml, with minor week to week variation. One week following the injection, Epo levels had increased to 4.5 mIU/ml for baboon 1 and over 6 mIU/ml for baboon 2 and by week 4, values had increased to 11.8 and 11.3 mIU/ml. Values peaked at week 8-10, at which time baboon 1 had circulating levels of 35.9 mIU and baboon 2 had 40.2 mIU/ml. Although the circulating Epo levels decreased in both baboons after week 12, levels remained above the pre-injection levels to week 26, at which point baboon 1 had circulating Epo levels of 5 mIU and baboon 2 had levels of 8.5 mIU. Throughout this period values ranged between 5 and 10 mIU, this compares with the pre-injection values of 1-3 mIU/ml. Animals injected with control rAAV-LacZ virus did not show any increase in serum Epo levels (data not shown).
Before treatment, the hematocrit of baboon 1 ranged from 35.7-40.0% and baboon 2 ranged from 38.7-42.3% (Figure 4b ). Despite the presence of elevated serum Epo levels, the hematocrits of both baboons did not increase significantly during the first week. This probably reflects the lag between exposure to Epo and differentiation of precursor cells into erythrocytes. By week 4, the hematocrits of both baboons had increased above the range seen before injection. Hematocrits continued to increase until week 10 at which time both baboons showed at least 25 point increase over their pretreatment levels. The hematocrit of baboon 2 exceeded 70% and thus this animal was phlebotomized to reduce the risk of thrombosis. Following phlebotomy, in which 34 ml of blood was drawn, hematocrit levels in this monkey continued to rise to week 13. The monkey was again phlebotomized at week 13, only to recover to pre-phlebotomy levels by week 14. From week 14 to week 28 the hematocrit levels in this baboon stabilized between 60-70 without phlebotomy. The hematocrit level of baboon 1 reached 61.6 at week 10 and remained elevated in the 60-70% range throughout the course of the study. It is interesting that the hematocrit levels stabilized in this animal which was not phlebotomized. This stabilization occurred despite elevated levels of circulating Epo (Figure 4) .
Discussion
Our results demonstrate the potential of AAV vectors to transduce skeletal muscle efficiently, resulting in longterm, stable protein expression in mouse and nonhuman primates. In mice, following rAAV-cm-Epo injection, expression of Epo protein is evident from the earliest time-point tested and continues through the course of the study (12 weeks). The hematocrit levels of 90% were maintained in these mice from week 7 onwards. It is surprising that rodents can tolerate such high hematocrits without untoward consequences, such as stroke, which is a common sequel of polycythemia in humans. 21 Our results in C57BL/6 mice contrast with a recently published report using rAAV to deliver a human Epo cDNA. 10 This report demonstrated long-term expression of human Epo in BALB/c mice while in C57BL/6 mice a decrease in circulating reticulocytes and fatal anemia were observed. In contrast, we demonstrate long-term expression of monkey Epo in C57BL/6 mice ( Figure 2 ) following intramuscular delivery. We were unable to detect significant amounts of antibodies against monkey Epo in the serum of C57BL/6 mice treated with rAAVcm-Epo. The lack of immune response in C57BL/6 mice is not surprising since there are several reports in the literature regarding the varied immune response in this strain of mice to multiple antigens delivered by adenoviral vectors. [22] [23] [24] [25] These results highlight the important influence of mouse haplotype on the generation of immune response against a foreign transgene.
Our results in baboons demonstrate, for the first time, the utility of rAAV vectors to deliver therapeutic genes by the i.m. route in primates. We chose the i.m. route of delivery due to the easy accessibility and large surface area available for gene delivery and expression. Baboons weighing 150× more than mice (approximately 3.5 and 4.0 kg) were given a dose of 2 × 10 12 particles, which is approximately 10-fold higher than the dose used in mice. As early as 1 week following i.m. delivery of rAAV particles, the level of circulating Epo increased significantly. As we previously noticed in mice, the hematocrit rise trailed protein expression. This lag, which is also seen with recombinant protein injection, reflects the time it takes for expansion and differentiation of erythroid progenitor cells. The next hematocrit time-point (4 week) clearly demonstrated a significant increase which also correlated with an increase in circulating Epo. The maximum circulating levels of Epo in these baboons are at least 10-15-fold higher than pre-injection levels. Hematocrit levels in the treated baboons rose to levels which were almost two-fold higher than the pre-injection levels. These significant increases reflect the robust gene expression which follows rAAV delivery.
It is interesting that it took more than 8 weeks for Epo expression to reach maximum levels. Similar delays are seen following intramuscular injection of AAV into rodents. It is possible that this delay reflects a delay in the conversion of the single-stranded AAV genome into transcriptionally active double-stranded DNA. Another possibility is that the vector infects a replicating target cell and that the increase in expression results from an expansion of cells containing integrated viral genomes.
Expression of Epo declines between weeks 8 and 12 before reaching a steady state level of approximately 5-10 mIU which persists to week 26. This level is higher than the pre-injection steady state level of 1-3 mIU. Currently, we do not know why expression follows these kinetics. We have analyzed the sera of treated baboons at various time-points after injection and we have not been able to detect antibodies against erythropoietin (data not shown). It is possible that a population of cells which is infected at early time-points has a limited life span or that expression is shut down in a subpopulation of infected cells. Another possibility is that only a subset of rAAV genomes are capable of persisting through integration or concatamerization. It should be noted that this decline in expression in baboons has not been seen in rodent models following intramuscular injection.
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We did not see a decline in hematocrit which corresponded to the decline in serum Epo levels. Since it has been 16 weeks (112 days) from the initial decline in Epo levels, it is unlikely that this continued elevation of hematocrit is due to the slow turnover (life span of approximately 120 days) of red blood cells. 26 The elevated steady state may reflect the fact that the levels of circulating Epo are sufficient to replenish lost red blood cells. Svensson et al 27 have recently shown that mice treated with an adenoviral vector expressing mouse Epo maintained elevated hematocrit for 11 weeks following a five-fold drop in serum Epo levels. It is possible that a similar mechanism is operating in nonhuman primates.
It is interesting to compare our results with those obtained by Svensson et al 27 in nonhuman primates. These workers injected an adenoviral vector expressing the cynomolgus monkey Epo gene into the muscle of a cynomolgus monkey. Injection of 4 × 10 11 p.f.u. of this adenoviral vector produced effects which were similar to those obtained by injection of 10 12 particles of rAAV. In both cases, hematocrits reached 70% by week 8 and the measured Epo level was approximately 50 mIU (day 84).
The standard course of Epo treatment for anemia in humans is a bolus injection of 100 U/kg of body weight administered three times a week. This dose leads to 1-2% increase in the hematocrit per week. In our study a single injection of rAAV encoding Epo in baboons results in a steady hematocrit increase of 2.5-3.5% per week for the first 10 weeks. Thus, continuous production of recombinant Epo following administration of rAAV vectors in the muscle may have a pharmacokinetic advantage over the bolus administration of recombinant protein. To accomplish appropriate therapeutic levels of the gene product in the circulation by rAAV vectors, new strategies, such as varying vector dose and/or regulatable promoter-driven constructs can be envisioned.
In conclusion, we have accomplished long-term, efficient gene delivery in nonhuman primates following intramuscular delivery of rAAV-encoding monkey Epo. Our experiments in baboons will facilitate designing human clinical trials with rAAV-based vectors. Further studies to establish parameters for regulated gene expression and long-term safety will facilitate human clinical trials.
Materials and methods
Vector constructs, viruses and cell lines Monkey Epo clone pCMVAAV-cm-Epo was generated by cloning the AvrII-BglII fragment from the clone pMKE83 (ATCC accession number 67545) into XbaI-BamHI sites of an AAV cloning vector pKM201CMV. 28 The AAV helper plasmid, pKSrep/cap (encoding rep and cap protein), was constructed by cloning the AAV-2 genome, without the ITRs (AAV-2 nucleotides 192-4493) into pBluescript II KS+ (Stratagene, La Jolla, CA, USA).
rAAV production rAAV vectors were produced by a modified transient plasmid transfection protocol. 29, 30 Briefly, human embryonic kidney 293 cells, grown to 60% confluence in a 15-cm dish, were co-transfected with 12.5 g of helper plasmid pKS rep/cap and 12.5 g of vector plasmid pCMVAAV-cm-Epo by the calcium phosphate co-precipitation method. The precipitate was left on the cells for 8 h and the medium was replaced with IMDM + 10% FBS containing adenovirus type 5 dl312 at a multiplicity of infection (MOI) of 2. Seventy-two hours after infection, the cells were harvested in HEPES buffer (2.5 ml per dish) and lysed by three cycles of freezing and thawing. The cell lysate was centrifuged at 2000 g for 20 min to remove cell debris. The packaged rAAV virus was purified through two rounds of cesium chloride equilibrium density gradients to remove adenoviral particles and contaminating proteins. The purified viral stock was heated at 56°C for 45 min to inactivate residual adenovirus particles. The DNase resistant vector particle number was calculated by dot blot hybridization protocol.
In vitro analysis of recombinant AAV erythropoietin (rAAV-cm-Epo) HT1080 cells (human fibrosarcoma cell line) maintained in DME + 10% FCS were plated (2 × 10 5 cells) on a sixwell dish day before infection. Cells were infected with rAAV at different MOI and 48 h supernatant was monitored for Epo using the R&D Quantikine ELISA kit (R& D Systems, Minneapolis, MN, USA).
In vivo administration of rAAV-cm-Epo into murine skeletal muscle Seven-week-old female C57BL/6 mice were obtained from Charles River Laboratories (Wilmington, MA, USA). rAAV was administered by injection of 50 l of normal saline or normal saline containing 2 × 10 11 rAAV particles into the tibialis anterior (TA) muscle of mice anesthetized with a mixture of ketamine and xylazine.
In vivo administration of rAAV-cm-Epo into Baboon skeletal muscle Experiments were conducted at the Southwest Foundation for Biomedical Research (San Antonio, TX, USA). Two 1-year-old females, weighing between 3.5 and 4.0 kg, were used in the study. Animals were sedated with 10 mg/kg ketamine and 0.5 ml of a 2 x 10 12 particles/ml stock of rAAV-cm-Epo was injected into the tibialis anterior of both legs. As a control two baboons received similar amounts of rAAV vector encoding ␤-galactosidase gene. All procedures were performed in accordance with NIH and institutional guidelines.
Analysis of erythropoietin levels following in vivo delivery
In mouse experiments, blood (200 l) was collected by using retro-orbital bleeds following isoflurane sedation. Whole blood was used for hematocrit estimation and the separated serum was used for detecting the Epo by ELISA. In baboons, 2.5 ml of blood was collected for performing hematocrit and ELISA. The levels of Epo were determined from monkey plasma or mouse serum using the R&D Systems ELISA Quantikine kit (R&D Systems).
Detection of anti-monkey Epo antibodies
A bioluminescent immunoassay 32 was used to detect antibodies against Epo. Briefly, microtiter plates (Dynatech Microlite, Chantilly, VA, USA) were coated with 50 l of Epogen (Epoetin; Amgen, Thousand Oaks, CA, USA) in a 1 g/ml solution in PBS and incubated overnight at 4°C or for 1 h at 37°C. The coated wells were blocked with 1 × Aqualite streptavidin assay buffer (Sealite Sciences, Bogard, GA, USA) containing 5% goat serum for 1 h at 37°C. The plates were then washed 3 × with 1 × Aqualite washing buffer containing 1% goat serum and 3% Tween-20. Diluted serum samples (50 l) were transferred on to coated plates and incubated at 37°C for 1 h, then washed 6 × with washing buffer. Primary antibody (goat anti-mouse IgG from Sigma, St Louis, MO, USA) diluted to 1:1000 was added and incubated for 1 h followed by washing (6 ×). Streptavidin Aqualite antibody (1:500) was added to each well and incubated at 37°C for 1 h followed by washing (6 ×). The luminescence was triggered by injections of 50 l aliquots of 1 × trigger buffer and the plates were read with a Dynatech ML3000 luminometer.
